title: Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
abstract: BACKGROUND
  Olanzapine associated weight gain (WG) is a major concern in patients with schizophrenia. The purpose of this study was to assess the efficacy of topiramate to prevent olanzapine induced WG in these cases. We also studied various metabolic parameters.
  
  
  METHODS
  In this 12-week, double-blind, parallel group study, seventy-two drug-naïve, first-episode schizophrenia patients were randomized to receive olanzapine+placebo (olanzapine group) or olanzapine+topiramate (100mg/day) (topiramate group). Weight, body mass index, fasting glucose, insulin, insulin resistance (IR), leptin, lipids and blood pressure were assessed at baseline and at 12 weeks. The patients were clinically evaluated using Positive and Negative Syndrome Scale (PANSS) and were monitored for adverse effects.
  
  
  RESULTS
  Topiramate resulted in a weight loss of 1.27+/-2.28 kg (p<0.01), decrease in leptin (p<0.001), glucose, cholesterol, triglyceride levels and systolic and diastolic blood pressure. In the olanzapine group, there was a significant WG, hyperglycemia, hyperinsulinemia, increased IR, hyperleptinemia, hypercholesterolemia and hypertriglyceridemia (p<0.001).There was a greater clinical improvement (PANSS scores) (p<0.001) in the topiramate group. The adverse effects were well tolerated.
  
  
  CONCLUSIONS
  Topiramate could prevent olanzapine induced weight gain and adverse metabolic effects. It also results in a greater clinical improvement when used with olanzapine in schizophrenia.
authors.affiliation: Department of Pharmacology, Lady Hardinge Medical College and Associated SSK Hospitals, New Delhi, India. docpreeta@yahoo.com
authors.forename: Preeta Kaur
authors.initials: PK
authors.lastname: Narula
authors.forename: H S
authors.initials: HS
authors.lastname: Rehan
authors.forename: K E S
authors.initials: KE
authors.lastname: Unni
authors.forename: Neeraj
authors.initials: N
authors.lastname: Gupta
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D000077152:Olanzapine; D011446:Prospective Studies; D012559:Schizophrenia / Q000188:drug therapy; D000077236:Topiramate; D015430:Weight Gain / Q000187:drug effects*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D018696:Neuroprotective Agents; D000077236:Topiramate; D001569:Benzodiazepines; D005632:Fructose; D002784:Cholesterol; D000077152:Olanzapine